We are live on
!
Find out more
BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
Turnover
16.91%
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.65%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$5.73M
(+4.5%)
Cap. Flow
-$179K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
31.6%
Holding
141
New
11
Increased
30
Reduced
56
Closed
10
Avg Time Held Equity + Options
3
years
Top 10 Avg Time Held Equity + Options
1.8
years
Top 20 Avg Time Held Equity + Options
2.3
years
Avg Time Held Equity only
3
years
Top 10 Avg Time Held Equity only
1.8
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$1.64M |
| 2 |
Newell Brands
NWL
|
+$1.16M |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.05M |
| 4 |
Apple
AAPL
|
+$1.02M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1,000K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$1.44M |
| 3 |
Viasat
VSAT
|
+$1.26M |
| 4 |
iShares Europe ETF
IEV
|
+$1.17M |
| 5 |
Novartis
NVS
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 17.42% |
| 2 | Technology | 15.72% |
| 3 | Real Estate | 14.11% |
| 4 | Healthcare | 13.29% |
| 5 | Financials | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Dell
DELL
$301B
| $254K | 0.19% |
+10,690
| New | +$236K |
2018 Q2
0 quarters
|
|
102
Invesco Aerospace & Defense ETF
PPA
$7.56B
| $253K | 0.19% |
4,600
+300
| +7% | +$17K |
2017 Q2
4 quarters
|
|
103
Caterpillar
CAT
$338B
| $244K | 0.18% |
+1,800
| New | +$269K |
2018 Q2
0 quarters
|
|
|
VWTR
104
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
| $244K | 0.18% |
20,957
-5,000
| -19% | -$57.1K |
2016 Q1
9 quarters
|
|
|
LGF.B
105
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $235K | 0.18% |
+10,000
| New | +$232K |
2018 Q2
0 quarters
|
|
106
INNOVATE Corp
VATE
$84.7M
| $234K | 0.18% |
4,000
| – | – |
2016 Q3
7 quarters
|
|
|
MIN
107
Aberdeen Intermediate Income Fund
MIN
$267M
| $233K | 0.18% |
10,050
-667
| -6% | -$15.5K |
2013 Q2
20 quarters
|
|
108
State Street Health Care Select Sector SPDR ETF
XLV
$45.9B
| $225K | 0.17% |
2,700
-400
| -13% | -$33.1K |
2014 Q4
14 quarters
|
|
|
AABA
109
DELISTED
Altaba Inc
AABA
| $220K | 0.17% |
+3,000
| New | +$225K |
2018 Q2
0 quarters
|
|
110
DELISTED
Nuveen Pennsylvania Quality Municipal Income Fund
NQP
| $210K | 0.16% |
16,600
| – | – |
2017 Q2
4 quarters
|
|
111
iShares Dow Jones US ETF
IYY
$3.03B
| $205K | 0.16% |
+3,000
| New | +$203K |
2018 Q2
0 quarters
|
|
112
Center Bancorp
CNOB
$1.53B
| $204K | 0.15% |
8,206
| – | – |
2017 Q3
3 quarters
|
|
113
Element Solutions
ESI
$8.66B
| $145K | 0.11% |
12,500
-2,500
| -17% | -$27.3K |
2015 Q4
10 quarters
|
|
114
BioLineRX
BLRX
$10.2M
| $127K | 0.1% |
238
| – | – |
2014 Q1
17 quarters
|
|
115
abrdn Asia-Pacific Income Fund
FAX
$530M
| $111K | 0.08% |
4,300
-367
| -8% | -$9.97K |
2013 Q2
20 quarters
|
|
|
TOO
116
DELISTED
Teekay Offshore Partners L.P.
TOO
| $107K | 0.08% |
40,500
-30,000
| -43% | -$79.6K |
2015 Q4
10 quarters
|
|
|
TRIB
117
Trinity Biotech
TRIB
$6.45M
| $99K | 0.07% |
132
-21
| -14% | -$15.2K |
2013 Q2
20 quarters
|
|
|
BNBX
118
DELISTED
BNB PLUS CORP
BNBX
| – | – |
0
| – | – |
2015 Q2
12 quarters
|
|
119
Global Ship Lease
GSL
$1.51B
| $60K | 0.05% |
5,669
| – | – |
2014 Q4
14 quarters
|
|
120
Celldex Therapeutics
CLDX
$2.27B
| $27K | 0.02% |
3,627
-40
| -1% | -$535 |
2015 Q4
10 quarters
|
|
|
PDL.B
121
DELISTED
PRESIDENTAL RLTY CL B
PDL.B
| $3K | ﹤0.01% |
74,000
| – | – |
2013 Q2
20 quarters
|
|
122
Colgate-Palmolive
CL
$73.9B
| – | – |
-5,000
| Closed | -$358K | – |
|
123
iShares Core High Dividend ETF
HDV
$15.4B
| – | – |
-12,000
| Closed | -$203K | – |
|
|
124
iShares Europe ETF
IEV
$1.6B
| – | – |
-25,045
| Closed | -$1.17M | – |
|
125
Johnson Controls International
JCI
$89.4B
| – | – |
-13,900
| Closed | -$490K | – |
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Benchmark Capital Advisors held 141 positions worth $132M, up 4.5% from $127M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Benchmark Capital Advisors's Q2 2018 filing shows 11 new, 30 increased, 56 reduced and 10 closed positions. Its largest new stake was Merck: 29,082 shares worth $1.68M. The largest sale was Bristol-Myers Squibb, an estimated $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 17% of assets, down from 20% a quarter earlier, followed by Technology and Real Estate.
- Benchmark Capital Advisors's largest Q2 2018 buy was Merck: 29,082 shares worth $1.68M.
- Benchmark Capital Advisors added most to Meta Platforms (Facebook) in Q2 2018, an estimated $1.05M increase.
- Benchmark Capital Advisors's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $2.2M.
- Benchmark Capital Advisors fully exited Viasat in Q2 2018, selling an estimated $1.26M.
- Benchmark Capital Advisors's ten largest holdings make up 32% of its $132M portfolio in Q2 2018.
- Benchmark Capital Advisors opened 11 new positions and closed 10 in Q2 2018.
- Benchmark Capital Advisors's portfolio value rose 4.5% quarter-over-quarter to $132M.
Based on Benchmark Capital Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.